Determinants of Headache in Lansoprazole Users in The Netherlands
- PDF / 135,303 Bytes
- 9 Pages / 505 x 720 pts Page_size
- 43 Downloads / 166 Views
Drug Safety 2002; 25 (4): 287-295 0114-5916/02/0004-0287/$25.00/0 © Adis International Limited. All rights reserved.
Determinants of Headache in Lansoprazole Users in The Netherlands Results from a Nested Case-Control Study Angela A.M.C. Claessens,1,2 Eibert R. Heerdink,1 Jacques T.H.M. van Eijk,3 Cornelis B.H.W. Lamers4 and Hubert G.M. Leufkens1 1 Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht, The Netherlands 2 Kendle, Utrecht, The Netherlands 3 Department of Medical Sociology, Health Care Studies, Faculty of Medicine, University of Maastricht, Maastricht, The Netherlands 4 Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, The Netherlands
Abstract
Objective: During proton pump inhibitor (PPI) use, in clinical trials, headache is one of the most frequently reported adverse events (frequency 1.3 to 8.8%), while results of one observational study indicate that headache is the fifth most frequently reported adverse event (incidence densities 2.5 to 4.6 per 1000 patientmonths of exposure). However, there are no observational studies performed regarding the occurrence and features of headache during use of PPIs in daily practice. For this reason this study was set up with the aim to assess the incidence and characteristics of headache and to investigate possible associated co-factors in PPI users in daily practice. Design: Data were used from a prospective, observational study in which 10 008 lansoprazole users were followed over time. The study was designed according to the Safety Assessment of Marketed Medicines guidelines. A nested case-control design was used to compare PPI users reporting headache or not. Results: The frequency of headache was 2.5% in users of lansoprazole and the incidence density was 7.2 per 1000 patient-months of PPI lansoprazole use. Twothirds of patients with headache had tension headache and one-third had migraine. The analysis of co-factors revealed that women, patients with previous use of analgesics and patients reporting several adverse events, were at risk to develop headache during PPI use. Patients with headache also, significantly more often, reported diarrhoea, nausea and dizziness. A discontinuation of PPI therapy resulted in a cessation or reduction of the headache in 80.0% (20 of 25). Conclusions: As can be expected, headache was reported less frequently in this study compared with clinical trials with lansoprazole. The incidence density was comparable with other observational data of lansoprazole and omeprazole users. Besides several commonly accepted co-factors such as female gender and a history of analgesic use, we also found the reporting of other adverse events to be associated with the reporting of headache during lansoprazole use. The cessation of headache after a discontinuation of use of the PPI and the observed dose relationship suggested that headache was indeed an adverse effect of lansoprazole use.
288
The proton pump inhibitor (PPI) lansoprazole was i
Data Loading...
